Greetings Readers,
Today's top stock is Intelligent Bio Solutions Inc. (NASDAQ: INBS). Read on for our analysis and why we love it.
Markets Grind Out A Weekly Win As Chips Wobble And Iran Tensions Simmer
The S&P 500 closed Friday at 7,575.39, up 0.42 percent on the day and enough to lock in a weekly gain. The Nasdaq Composite finished at 26,281.61. The Dow Jones Industrial Average added 149.60 points to close at 52,637.01.
The week's headline event was SK Hynix's Nasdaq debut, the largest foreign IPO in U.S. history at $26.5 billion, with shares popping double digits out of the gate. That kept the AI trade in focus even as renewed U.S. and Iran tensions kept oil traders on edge.
Underneath the index gains, the action was choppy. Chip names swung hard through the week, and healthcare and industrial stocks lagged while communications and financials led.
That kind of rotation is exactly why small, fundamentally driven names can get overlooked. One that should not be is Intelligent Bio Solutions.
INBS is a New York-based medical technology company built around a simple idea. Instead of urine cups or lab draws, the Intelligent Fingerprinting Drug Screening System reads sweat off a fingertip and delivers a result in under ten minutes.
The system screens for opiates, cocaine, methamphetamine, cannabis, and benzodiazepines with 100 percent specificity and 94.1 percent accuracy in company testing. It is already sold internationally through a portable reader and single-use cartridge model, and the company is now pushing hard toward FDA clearance to open the U.S. drug screening market.
Technical Levels To Take Advantage Of
Price is currently sitting at $2.19.
The first level to watch is $2.40.
Beyond that, $2.62 is the next resistance to clear.
And above that, $2.78 comes into play.
Support sits at $2.09. A break below that level would put the stock back into its 52 week low range and shift the near term picture.
What Caught My Attention
On December 31, 2025, Syrma Johari manufacturing deal, paired with a $10 million private placement, was never just a one-day trading story. The projected cost savings and margin lift from that agreement have now shown up directly in the numbers, with fiscal Q3 2026 gross margin hitting 50.5 percent following the first reader shipments under the new partnership in late February 2026.
These developments, combined with the technical levels above, make this a name worth serious attention.
Before We Wrap Up
As always, make sure to do your own research on INBS before making any investment decision with risk.
I will be back next week with more market news.
Sincerely,
Chris Forson